Early immune response to COVID may block virus before antibodies form

Researchers found that T cells targeting the coronavirus's nucleocapsid protein can control SARS-CoV-2 in the upper airways before the body produces detectable antibodies. The finding could reshape vaccine design and diagnostic strategies, suggesting immunity develops faster than current tests can measure.

Originaltitel: Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion